Literature DB >> 24312751

Vasorelaxant Effect of a Newly Synthesized Dihydropyridine Ethyl Ester (DHPEE) on Rat Thoracic Aorta: Dual Mechanism of Action.

Hossein Babaei1, Farzaneh Ebrahimi, Javid Shahbazi Mojarrad, Yadollah Azarmi, Afsaneh Gharehbagheri.   

Abstract

INTRODUCTION: DHPEE is a newly synthesized compound by merging the key structural elements in an angiotensin receptor blocker (Telmisartan) with key structural elements in 1,4- dihydropyridine calcium channel blocker (Nifedipine). In this study, we examined dual calcium channel blocking and AT1 antagonist activity for DHPEE.
METHODS: The functional inhibitory characteristics of DHPEE were studied in vitro in rat thoracic aorta preparations precontracted by phenylephrine (1μM) or KCl (80μM) or Ang II in normal or calcium-free solutions.
RESULTS: Concentration-dependent significant relaxation was observed in aortic rings precontracted with phenylephrine, KCl or Ang II. The tension increment produced by increasing external calcium was also reduced by DHPEE. DHPEE caused a marked decrease in the maximal contractile response of the vasoactive agents and shifted their concentration-response curves to the right.
CONCLUSION: DHPEE possesses dual characteristics and cause vasorelaxation by blocking the L-type calcium channels and blocking Ang II receptors (AT1) in rat aortic smooth muscle.

Entities:  

Keywords:  Angiotensin II; Angiotensin Receptor blocker; Calcium Channel blocker; DHPEE; Rat Aorta

Year:  2011        PMID: 24312751      PMCID: PMC3849999          DOI: 10.5681/apb.2011.002

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  31 in total

1.  Cytosolic Calcium Oscillations in Smooth Muscle Cells.

Authors:  Jean-Pierre Savineau; Roger Marthan
Journal:  News Physiol Sci       Date:  2000-02

Review 2.  Smooth muscle contraction and relaxation.

Authors:  R Clinton Webb
Journal:  Adv Physiol Educ       Date:  2003-12       Impact factor: 2.288

3.  Calcium-activated potassium channels in single smooth muscle cells of rabbit jejunum and guinea-pig mesenteric artery.

Authors:  C D Benham; T B Bolton; R J Lang; T Takewaki
Journal:  J Physiol       Date:  1986-02       Impact factor: 5.182

4.  Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Authors:  Toshihiko Ishimitsu; Atsushi Numabe; Toshihide Masuda; Tomoyuki Akabane; Atsushi Okamura; Junichi Minami; Hiroaki Matsuoka
Journal:  Hypertens Res       Date:  2009-08-21       Impact factor: 3.872

Review 5.  Characteristics and physiological role of the Ca(2+)-activated Cl- conductance in smooth muscle.

Authors:  W A Large; Q Wang
Journal:  Am J Physiol       Date:  1996-08

6.  Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta.

Authors:  K Inoue; H Nishimura; J Kubota; Y Kitaura
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2000-06       Impact factor: 1.636

7.  Angiotensin II-induced aortic ring constriction is mediated by phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway.

Authors:  Kee Hun Do; Min Sung Kim; Jae Ho Kim; Byung Yong Rhim; Won Suk Lee; Chi Dae Kim; Sun Sik Bae
Journal:  Exp Mol Med       Date:  2009-08-31       Impact factor: 8.718

8.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

Review 9.  Differences in cardiovascular profile among calcium antagonists.

Authors:  N Taira
Journal:  Am J Cardiol       Date:  1987-01-30       Impact factor: 2.778

Review 10.  Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker.

Authors:  George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

View more
  1 in total

1.  Vasorelaxant effect of 17α-ethynylestradiol on human saphenous vein.

Authors:  Ahmad Reza Jodati; Hossein Babaei; Yadollah Azarmi; Sahar Fallah; Afsaneh Gharebageri; Danial Fadaei Fouladi; Naser Safaei
Journal:  Adv Pharm Bull       Date:  2015-03-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.